TELA Bio Appoints New CFO, Kevin J. O'Malley
Ticker: TELA · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, cfo, compensation
TL;DR
TELA Bio just hired a new CFO, Kevin O'Malley, starting June 3rd. He's getting $400k base + bonus + stock options.
AI Summary
On May 30, 2025, TELA Bio, Inc. announced the appointment of Kevin J. O'Malley as its new Chief Financial Officer, effective June 3, 2025. O'Malley will receive an annual base salary of $400,000 and will be eligible for a discretionary annual bonus. He will also be granted stock options to purchase 150,000 shares of the company's common stock.
Why It Matters
The appointment of a new CFO is a significant leadership change that could impact the company's financial strategy and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and operational execution.
Key Numbers
- $400,000 — CFO Base Salary (Annual compensation for Kevin J. O'Malley)
- 150,000 — Stock Options (Granted to new CFO)
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- Kevin J. O'Malley (person) — Newly appointed Chief Financial Officer
- $400,000 (dollar_amount) — Annual base salary for new CFO
- June 3, 2025 (date) — Effective date for new CFO
- 150,000 (dollar_amount) — Number of stock options granted to new CFO
FAQ
Who is the new Chief Financial Officer of TELA Bio, Inc.?
Kevin J. O'Malley has been appointed as the new Chief Financial Officer of TELA Bio, Inc.
When does Kevin J. O'Malley's appointment as CFO become effective?
Kevin J. O'Malley's appointment is effective June 3, 2025.
What is the annual base salary for the new CFO?
The annual base salary for Kevin J. O'Malley is $400,000.
What other compensation will the new CFO receive?
Kevin J. O'Malley will be eligible for a discretionary annual bonus and will be granted stock options to purchase 150,000 shares of the company's common stock.
What is the filing date of this 8-K report?
This 8-K report was filed on June 2, 2025, reporting events as of May 30, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 by Kevin J. O'Malley regarding TELA Bio, Inc. (TELA).